KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Treasury Shares (2018 - 2025)

Vir Biotechnology's Treasury Shares history spans 8 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 14.23% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $5.7 million, up 14.23%, while the annual FY2025 figure was $5.7 million, 14.23% up from the prior year.
  • Treasury Shares for Q4 2025 was $5.7 million at Vir Biotechnology, up from $5.0 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $5.7 million in Q4 2025 and bottomed at $36298.0 in Q1 2021.
  • The 5-year median for Treasury Shares is $2.7 million (2022), against an average of $2.9 million.
  • The largest annual shift saw Treasury Shares tumbled 97.51% in 2021 before it soared 7452.44% in 2022.
  • A 5-year view of Treasury Shares shows it stood at $1.3 million in 2021, then surged by 109.84% to $2.7 million in 2022, then soared by 80.11% to $4.8 million in 2023, then grew by 3.67% to $5.0 million in 2024, then grew by 14.23% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Treasury Shares are $5.7 million (Q4 2025), $5.0 million (Q4 2024), and $4.8 million (Q4 2023).